![SPRAVATO®▽ approved for reimbursement in Ireland for adults with treatment-resistant major depressive disorder SPRAVATO®▽ approved for reimbursement in Ireland for adults with treatment-resistant major depressive disorder](https://d1l0gza1nowsqe.cloudfront.net/wp-content/uploads/sites/4/2022/05/Spravato6001PPS0_620.jpg)
SPRAVATO®▽ approved for reimbursement in Ireland for adults with treatment-resistant major depressive disorder
![SPRAVATO®▽ (Esketamine) Nasal Spray Approved in Europe for Adults with Treatment-Resistant Major Depressive Disorder | Business Wire SPRAVATO®▽ (Esketamine) Nasal Spray Approved in Europe for Adults with Treatment-Resistant Major Depressive Disorder | Business Wire](https://mms.businesswire.com/media/20191219005272/en/764047/4/WebReady480.jpg)
SPRAVATO®▽ (Esketamine) Nasal Spray Approved in Europe for Adults with Treatment-Resistant Major Depressive Disorder | Business Wire
![Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States | Psychiatric Services Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States | Psychiatric Services](https://ps.psychiatryonline.org/cms/10.1176/appi.ps.201900625/asset/images/medium/appi.ps.201900625f1.gif)
Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States | Psychiatric Services
![NHS rejects ketamine for depression as psychiatrists accuse NICE of mental health discrimination | Daily Mail Online NHS rejects ketamine for depression as psychiatrists accuse NICE of mental health discrimination | Daily Mail Online](https://i.dailymail.co.uk/1s/2022/09/17/15/62509625-11222317-image-a-18_1663425907764.jpg)